» Articles » PMID: 30890599

Clinical and Morphological Predictors of Outcome in Older Aplastic Anemia Patients Treated with Eltrombopag

Citing Articles

Determinants of COVID-19 Disease Severity-Lessons from Primary and Secondary Immune Disorders including Cancer.

Solimando A, Bittrich M, Shahini E, Albanese F, Fritz G, Krebs M Int J Mol Sci. 2023; 24(10).

PMID: 37240091 PMC: 10218128. DOI: 10.3390/ijms24108746.


Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow.

Solimando A, Palumbo C, Pragnell M, Bittrich M, Argentiero A, Krebs M Int J Mol Sci. 2022; 23(19).

PMID: 36233062 PMC: 9569739. DOI: 10.3390/ijms231911765.


Paroxysmal nocturnal hemoglobinuria-phenotype cells predict a good response to eltrombopag in patients with refractory aplastic anemia.

Ishiyama K, Sato K, Imi T, Hosokawa K, Kondo Y, Sugimori N EJHaem. 2022; 1(1):243-248.

PMID: 35847715 PMC: 9175921. DOI: 10.1002/jha2.51.


Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.

Li R, Zhou J, Liu Z, Chen X, Long Q, Yang Y Front Immunol. 2022; 13:884312.

PMID: 35720405 PMC: 9204341. DOI: 10.3389/fimmu.2022.884312.


Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia.

Yang W, Zhao X, Peng G, Zhang L, Jing L, Zhou K Ann Hematol. 2021; 100(10):2435-2441.

PMID: 34269836 DOI: 10.1007/s00277-021-04553-5.


References
1.
Uto Y, Fujiwara S, Arai N, Kawaguchi Y, Kabasawa N, Tsukamoto H . Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study. Rinsho Byori. 2015; 63(5):548-56. View

2.
Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A . Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2017; 103(2):212-220. PMC: 5792265. DOI: 10.3324/haematol.2017.176339. View

3.
Vaht K, Goransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A . Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017; 102(10):1683-1690. PMC: 5622852. DOI: 10.3324/haematol.2017.169862. View

4.
Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S . Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant.... Blood. 1999; 93(7):2191-5. View

5.
Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M . Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013; 123(12):1818-25. PMC: 3962161. DOI: 10.1182/blood-2013-10-534743. View